These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 12007956

  • 1. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
    Siemann DW, Rojiani AM.
    Int J Radiat Oncol Biol Phys; 2002 May 01; 53(1):164-71. PubMed ID: 12007956
    [Abstract] [Full Text] [Related]

  • 2. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
    Siemann DW, Rojiani AM.
    Int J Radiat Oncol Biol Phys; 2002 Dec 01; 54(5):1512-7. PubMed ID: 12459379
    [Abstract] [Full Text] [Related]

  • 3. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
    Siemann DW, Rojiani AM.
    Int J Radiat Oncol Biol Phys; 2005 Jul 01; 62(3):846-53. PubMed ID: 15936569
    [Abstract] [Full Text] [Related]

  • 4. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.
    Li L, Rojiani A, Siemann DW.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):899-903. PubMed ID: 9845118
    [Abstract] [Full Text] [Related]

  • 5. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.
    Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):835-42. PubMed ID: 15701874
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
    Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P.
    Mol Cancer Ther; 2004 Aug 15; 3(8):977-83. PubMed ID: 15299080
    [Abstract] [Full Text] [Related]

  • 8. Augmentation of radiation response with the vascular targeting agent ZD6126.
    Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM.
    Int J Radiat Oncol Biol Phys; 2006 Apr 01; 64(5):1458-65. PubMed ID: 16488554
    [Abstract] [Full Text] [Related]

  • 9. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.
    Horsman MR, Murata R.
    Int J Radiat Oncol Biol Phys; 2003 Nov 15; 57(4):1047-55. PubMed ID: 14575836
    [Abstract] [Full Text] [Related]

  • 10. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy.
    Masunaga S, Sakurai Y, Suzuki M, Nagata K, Maruhashi A, Kinash Y, Ono K.
    Int J Radiat Oncol Biol Phys; 2004 Nov 01; 60(3):920-7. PubMed ID: 15465210
    [Abstract] [Full Text] [Related]

  • 11. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.
    Cancer Res; 2002 Dec 15; 62(24):7247-53. PubMed ID: 12499266
    [Abstract] [Full Text] [Related]

  • 12. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
    Siemann DW, Mercer E, Lepler S, Rojiani AM.
    Int J Cancer; 2002 May 01; 99(1):1-6. PubMed ID: 11948484
    [Abstract] [Full Text] [Related]

  • 13. ZD6126: a novel small molecule vascular targeting agent.
    Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ.
    Int J Radiat Oncol Biol Phys; 2002 Dec 01; 54(5):1497-502. PubMed ID: 12459377
    [Abstract] [Full Text] [Related]

  • 14. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
    Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, Ryan AJ, Taraboletti G, Giavazzi R.
    Br J Cancer; 2007 Oct 08; 97(7):888-94. PubMed ID: 17848949
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
    Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ.
    Clin Cancer Res; 2002 Jun 08; 8(6):1974-83. PubMed ID: 12060643
    [Abstract] [Full Text] [Related]

  • 16. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
    Murata R, Siemann DW, Overgaard J, Horsman MR.
    Radiother Oncol; 2001 Aug 08; 60(2):155-61. PubMed ID: 11439210
    [Abstract] [Full Text] [Related]

  • 17. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors.
    Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP.
    Cancer Res; 2006 Feb 15; 66(4):2074-80. PubMed ID: 16489007
    [Abstract] [Full Text] [Related]

  • 18. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Clin Cancer Res; 2004 Nov 15; 10(22):7671-6. PubMed ID: 15570000
    [Abstract] [Full Text] [Related]

  • 19. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
    Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC.
    Clin Cancer Res; 2004 Jun 01; 10(11):3650-7. PubMed ID: 15173071
    [Abstract] [Full Text] [Related]

  • 20. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
    Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Cancer Res; 2002 Jul 01; 62(13):3711-5. PubMed ID: 12097279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.